209 results on '"Iacobelli, Simona"'
Search Results
2. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
3. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
4. Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients
5. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
6. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
7. A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party
8. ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications
9. Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry
10. Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up
11. Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT
12. Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT
13. Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT
14. Stem cell transplantation for chronic myeloid leukemia in children
15. Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party
16. Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party
17. Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT
18. Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)
19. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
20. An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors
21. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
22. Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT
23. Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party
24. A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma
25. Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT
26. Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma
27. Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia
28. Very Good Response and Overall Survival after Allogeneic Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis; Results of a Non-Interventional Study By the Plasma Cell Disorder Subcommittee of the Chronic Malignancy Working Party of the EBMT
29. Outcome of BONE Marrow Transplantation in Congenital Diskeratosis: Preliminary DATA from the European Group for BONE Marrow Transplantation (EBMT)
30. Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen
31. The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
32. Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party
33. Second Autologous Stem Cell Transplantation in Poor Stem Cell Mobilizers Multiple Myeloma Patients
34. Autoimmune Cytopenias (AIC) Following Allogeneic Haematopoietic Stem Cell Transplant for Acquired Aplastic Anaemia: A Joint Study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
35. Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT
36. Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers
37. Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)
38. Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT
39. Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties
40. Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis
41. EBMT Prospective Non-Interventional Study On Allogeneic Hematopoietic Stem Cell Transplantation In T-Prolymphocytic Leukemia (T-PLL). Preliminary Analysis Of 43 Patients
42. Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis
43. The Role Of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In Patients With POEMS Syndrome: A Retrospective study Of The Plasma Cell Disorders Subcommittee Of The Chronic Malignancy Working Party Of The EBMT
44. Comparison Of Intensive Chemotherapy and Hypomethylating Agents Prior To Allogeneic Stem Cell Transplantation For Advanced MDS (RAEB, RAEB-T). A Study Of The MDS Subcommittee Of The Cmwp Of EBMT
45. Kinetics of Engraftment and Predictors of Outcome in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL) After Treatment with Low Dose Total Body Irradiation (TBI) Followed by related or unrelated hematopoietic Stem Cell Transplantation
46. Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT
47. Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis,
48. A Comparison of Two Different Reduced Intensity Conditioning (RIC) Allograft Strategies In Patients with Multiple Myeloma, An EBMT Analysis
49. Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.
50. Primary Plasma Cell Leukaemia and Autologous Stem Cell Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.